SU 11274
-
SU 11274
structure -
-
CAS No:
658084-23-2
-
Formula:
C28Cl1H30N5O4S1
-
Chemical Name:
SU 11274
-
Synonyms:
PKI-SU11274;N-(3-Chlorophenyl)-N-methyl-3-[[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide;SU11274(PKI-SU11274);Sul1274;SU 11274,SU 11274;(Z)-N-(3-chlorophenyl)-3-((3,5-diMethyl-4-(4-Methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)Methylene)-N-Methyl-2-oxoindoline-5-sulfonaMide;(Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(1-methylpiperazine-4-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide;N-(3-Chlorophenyl)-N-methyl-3-[[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamideSU11274
- Categories:
-
CAS No:
Description
SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.
Safety Information
NONH for all modes of transport
3
36/37/38
26-36
Xi
P261-P305 + P351 + P338
H315-H319-H335
|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
Computed Properties
Molecular Weight:568.1
XLogP3:3.1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:5
Exact Mass:567.1707033
Monoisotopic Mass:567.1707033
Topological Polar Surface Area:114
Heavy Atom Count:39
Complexity:1070
Defined Bond Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Latest News on SU 11274
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
1-ETHYL-2 3-DIMETHYLIMIDAZOLIUM ETHYL SU
516474-08-1
-
5-Ethoxycarbonyl SU 5402 Methyl Ester
258831-76-4
-
Su 10603
786-97-0
-
Dabrafenib Formula
1195765-45-7
-
BOC-VAL-VAL-OH Formula
69209-73-0
-
BMS 303141 Formula
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Structure
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Structure
57899-96-4
-
What is 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea
26130-02-9
-
What is L-Tyrosyl-L-phenylalanine
17355-11-2
- Hot Searches
- propene
- k2o
- fusidic acid cream
- h2cro4
- potassium sulfide formula
- bromhexine